R&D

#FDA #Genetic diseases #Genetics #R&D

Sitting down with BridgeBio Pharma

Listen to this article on the DDW Podcast: Michael Henderson, MD, Chief Business Officer of BridgeBio Pharma, tells Lu Rahman about the company’s pursuit of transformative medicines to treat genetic diseases. BridgeBio’s mission is to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and… Read More

#Exclusive Content #Opinion

#Awards #Biopharmaceuticals #R&D

Global R&D challenge to accelerate scientific discovery and diversity

AstraZeneca has launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. Successful proposals will secure fully funded postdoctoral research positions. The challenge The challenge, launched at EXPO 2020 Dubai, invites final year MD and/or PhD students and… Read More

#News

#Biopharmaceuticals #Drug discovery #R&D #Therapeutics

Sitting down with… Dr Michael Hayden, Prilenia Therapeutics

Listen to this article on the DDW Podcast: Dr Michael Hayden's early encounters and experience with patients and families suffering from Huntington’s Disease has had a significant personal impact that shaped his career. As CEO of Prilenia Therapeutics, he tells Lu Rahman why he has dedicated his career to advancing research… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI / data analytics / healthtech / informatics #Biotechnology #Database #Drug development #R&D #Research

Bridging the gap between R&D teams in biotechnology   

Ashu Singhal, President & Co-Founder of Benchling, shares newly heightened expectations for the biotechnology industry following the developments of the last 18 months.   The last 18 months have heightened expectations for the biotechnology industry. Scientists came together to develop vaccines at record speeds and set the… Read More

#News

#Biotechnology #Drug development #Immunology / Virology & Vaccines #Microbiome #R&D

Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based… Read More

#News

#Drug discovery #R&D #Research

Brochure: Cubis laboratory balances in vaccine R&D 

A new brochure by Sartorius is now available to download.   Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save… Read More

#News

#Covid-19 #Drug development #Pharmaceuticals #R&D

Pharmaceutical industry warned not to undo pandemic advances 

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online… Read More

#News

#CRISPR #Drug development #Drug discovery #Gene editing #R&D

Benchling launch cloud solution at virtual event  

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More

#News

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing services. Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

#Antimicrobials #Drug development #Drug discovery #Infectious diseases #R&D

£1.9 million to combat infectious disease and antimicrobial resistance

The Bloomsbury SET, a knowledge exchange programme led by The Royal Veterinary College (RVC), has been awarded £1.9 million from Research England. Beginning in July 2021, the year-long project aims to commercialise research into infectious disease and antimicrobial resistance. Building on the current work of The Bloomsbury SET, this new… Read More

#News

#Animal testing #R&D #Research

FRAME comment on the new UK animal R&D statistics

The UK government has released a national statistics report, “Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020”. DDW recently reported the ABPI comment. The medical research charity FRAME’s Education & Outreach Manager Amy Beale has made further comment. Beale said: “Whilst the headline figures in the… Read More

#News

#AI #Biology #R&D #Therapeutics #Tumour biology

Combining AI-driven drug capabilities with CDK targets for oncology

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More

#News

#Animal testing #Biopharmaceuticals #R&D #Research

ABPI responds to new UK animal R&D statistics

The UK government has released a national statistics report, “Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020”. In summary, 2.88 million procedures were carried out in Great Britain involving living animals in 2020. Key results of the report include the fact that the 2.88 million procedures in… Read More

#News #Trending News

#Biopharma #Drug discovery #Life sciences #R&D

Abcam opens new US site

Abcam has opened a new site in Waltham, MA. The facility is a central part of Abcam’s growth in the US and will serve as a hub for its R&D and commercial activities in the region. “Abcam’s first step toward global expansion was in 2003 at Kendall Square.  Since then,… Read More

#News